Gene therapy for Wiskott-Aldrich syndrome: Rescue of T-cell signaling and amelioration of colitis upon transplantation of retrovirally transduced hematopoietic stem cells in mice

Blood

Volumn 101, Issue 6, 2003, Pages 2159-2166

  Klein, Christoph ^b   Nguyen, Deanna ^b   Liu, Ching Hui ^b   Mizoguchi, Atsushi ^b   Bhan, Atul K ^b   Miki, Hiroaki ^b   Takenawa, Tadaomi ^b   Rosen, Fred S ^b   Alt, Fred W ^b   Mulligan, Richard C ^b   Snapper, Scott B ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CELL PROLIFERATION; COLITIS; CONTROLLED STUDY; GENE MUTATION; GENE THERAPY; IMMUNE DEFICIENCY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; WISKOTT ALDRICH SYNDROME;

EID: 0037443395     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-05-1423     Document Type: Article

References (44)

1. Wiskott A. Familiärer, angeborener Morbus Werlhofii? Monatsschr. Kinderheilkd. 1937;68:212-216.
2. Aldrich RA, Steinberg AG, Campbell DC. Pedigree demonstrating a sex-linked recessive condition characterized by draining ears, eczematoid dermatitis and bloody diarrhea. Pediatrics. 1954; 13:133-139.
3. Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multiinstitutional survey of the WiskottAldrich syndrome. J Pediatr. 1994;125:876-885.
4. Derry JM, Ochs HD, Francke U. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell. 1994;78:635-644.
5. Miki H, Miura K, Takenawa T. N-WASP, a novel actin-depolymerizing protein, regulates the cortical cytoskeletal rearrangement in a PIP2-dependent manner downstream of tyrosine kinases. Embo J. 1996;15:5326-5335.
6. Miki H, Suetsugu S, Takenawa T. WAVE, a novel WASP-family protein involved in actin reorganization induced by Rac. Embo J. 1998;17:6932-6941.
7. Bear JE, Rawls JF, Saxe CL. SCAR, a WASP-related protein, isolated as a suppressor of receptor defects in late Dictyostelium development. J Cell Biol. 1998;142:1325-1335.
8. Snapper SB, Rosen FS. The Wiskott-Aldrich syndrome protein (WASP): roles in signaling and cytoskeletal organization. Annu Rev Immunol. 1999;17:905-929.
9. Rohatgi R, Ho HY, Kirschner MW. Mechanism of N-WASP activation by CDC42 and phosphatidylinositol 4, 5-bisphosphate. J Cell Biol. 2000;150:1299-1310.
10. Rohatgi R, Ma L, Miki H, et al. The interaction between N-WASP and the Arp2/3 complex links Cdc42-dependent signals to actin assembly. Cell. 1999;97:221-231.
11. Prehoda KE, Scott JA, Dyche Mullins R, Lim WA. Integration of multiple signals through cooperative regulation of the N-WASP-Arp2/3 complex. Science. 2000;290:801-806.
12. Kim AS, Kakalis LT, Abdul-Manan N, Liu GA, Rosen MK. Autoinhibition and activation mechanisms of the Wiskott-Aldrich syndrome protein. Nature. 2000;404:151-158.
13. Miki H, Sasaki T, Takai Y, Takenawa T. Induction of filopodium formation by a WASP-related actindepolymerizing protein N-WASP. Nature. 1998;391:93-96.
14. Gallego M, Santamaria M, Pena J, Molina I. Defective actin reorganization and polymerization of Wiskott-Aldrich T cells in response to CD3-mediated stimulation. Blood. 1997;90:3089-3097.
15. Molina IJ, Kenney DM, Rosen FS, Remold-O'Donnell E. T cell lines characterize events in the pathogenesis of the Wiskott-Aldrich syndrome. J Exp Med. 1992;176:867-874.
16. Molina IJ, Sancho J, Terhorst C, Rosen FS, Remold-O'Donnell E. T cells of patients with the Wiskott-Aldrich syndrome have a restricted defect in proliferative responses. J Immunol. 1993;151:4383-4390.
17. Badolato R, Sozzani S, Malacarne F, et al. Monocytes from Wiskott-Aldrich patients display reduced chemotaxis and lack of cell polarization in response to monocyte chemoattractant protein-1 and formyl-methionyl-leucyl-phenylalanine. J Immunol. 1998;161:1026-1033.
18. Zicha D, Allen WE, Brickell PM, et al. Chemotaxis of macrophages is abolished in the Wiskott-Aldrich syndrome. Br J Haematol. 1998;101:659-665.
19. Haddad E, Zugaza JL, Louache F, et al. The interaction between cdc42 and WASP is required for SDF-1-induced T-lymphocyte chemotaxis. Blood. 2001;97:33-38.
20. Snapper SB, Rosen FS, Mizoguchi E, et al. Wiskott-Aldrich syndrome protein-deficient mice reveal a role for WASP in T but not B cell activation. Immunity. 1998;9:81-91.
21. Zhang J, Shehabeldin A, da Cruz LA, et al. Antigen receptor-induced activation and cytoskeletal rearrangement are impaired in Wiskott-Aldrich syndrome protein-deficient lymphocytes. J Exp Med. 1999;190:1329-1342.
22. Buckley RH. Primary immunodeficiency diseases due to defects in lymphocytes. N Engl J Med. 2000;343:1313-1324.
23. Parkman R, Rappeport J, Geha R, et al. Complete correction of the Wiskott-Aldrich syndrome by allogeneic bone-marrow transplantation. N Engl J Med. 1978;298:921-927.
24. Ozsahin H, Le Deist F, Benkerrou M, et al. Bone marrow transplantation in 26 patients with Wiskott-Aldrich syndrome from a single center. J Pediatr. 1996;129:238-244.
25. Filipovich AH, Stone JV, Tomany SC, et al. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. Blood. 2001;97:1598-1603.
26. Huang MM, Tsuboi S, Wong A, et al. Expression of human Wiskott-Aldrich syndrome protein in patients' cells leads to partial correction of a phenotypic abnormality of cell surface glycoproteins. Gene Ther. 2000;7:314-320.
27. Candotti F, Facchetti F, Blanzuoli L, Stewart D, Nelson D, Blaese R. Retrovirus-mediated WASP gene transfer corrects defective actin polymerization in B cell lines from Wiskott-Aldrich syndrome patients carrying 'null' mutations [In Process Citation]. Gene Ther. 1999;6:1170-1174.
28. Ory DS, Neugeboren BA, Mulligan RC. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc Natl Acad Sci U S A. 1996;93:11400-11406.
29. Klein C, Bueeler HR, Mulligan RC. Comparative analysis of genetically modified dendritic cells and cytokine transduced tumor cells as therapeutic cancer vaccines. J Exp Med. 2000;191:1699-1708.
30. Dahl AM, Klein C, Andres PG, et al. Expression of Bcl-XL restores survival, but not proliferation and effector differentiation, in CD28-deficient T lymphocytes. J Exp Med. 2000;191:2031-2038.
31. Kolluri R, Tolias KF, Carpenter CL, Rosen FS, Kirchhausen T. Direct interaction of the Wiskott-Aldrich syndrome protein with the GTPase Cdc42. Proc Natl Acad Sci U S A. 1996;93:5615-5618.
32. Snapper S, Takeshima F, Anton I, et al. N-WASP-deficiency reveals distinct pathways for cell surface projections and the actin-based motility of intracellular microorganisms. Nat Cell Biol. 2001;3:898-904.
33. Mulligan RC. The basic science of gene therapy. Science. 1993;260:926-932.
34. Symons M, Derry JM, Karlak B, et al. Wiskott-Aldrich syndrome protein, a novel effector for the GTPase CDC42Hs, is implicated in actin polymerization. Cell. 1996;84:723-734.
35. Huang M, Wong A, Weinber K, Francke U, Kohn D. Expression of human Wiskott-Aldrich syndrome protein in patients' primary hematopoietic cells and EBV-transduced cell lines after retroviral vector-mediated gene transduction. Blood. 1997;90:263A.
36. Strom TS, Li X, Cunningham JM, Nienhuis AW. Correction of the murine Wiskott-Aldrich syndrome phenotype by hematopoietic stem cell transplantation. Blood. 2002;99:4626-4628.
37. Hsieh KH, Chang MH, Lee CY, Wang CY. Wiskott-Aldrich syndrome and inflammatory bowel disease. Ann Allergy. 1988;60:429-431.
38. Greer WL, Kwong PC, Peacocke M, Ip P, Rubin LA, Siminovitch KA. X-chromosome inactivation in the Wiskott-Aldrich syndrome: a marker for detection of the carrier state and identification of cell lineages expressing the gene defect. Genomics. 1989;4:60-67.
39. Gealy WJ, Dwyer JM, Harley JB. Alletic exclusion of glucose-6-phosphate dehydrogenase in platelets and T lymphocytes from a Wiskott-Aldrich syndrome carrier. Lancet. 1980;1:63-65.
40. Fearon ER, Kohn DB, Winkelstein JA, Vogelstein B, Blaese RM. Carrier detection in the Wiskott Aldrich syndrome. Blood. 1988;72:1735-1739.
41. Wengler G, Gorlin JB, Williamson JM, Rosen FS, Bing DH. Nonrandom inactivation of the X chromosome in early lineage hematopoietic cells in carriers of Wiskott-Aldrich syndrome. Blood. 1995;85:2471-2477.
42. Ariga T, Kondoh T, Yamaguchi K, et al, Spontaneous in vivo reversion of an inherited mutation in the Wiskott-Aldrich syndrome. J Immunol. 2001;166:5245-5249.
43. Wada T, Schurman SH, Otsu M, et al. Somatic mosaicism in Wiskott-Aldrich syndrome suggests in vivo reversion by a DNA slippage mechanism. Proc Natl Acad Sci U S A. 2001;98:8697-8702.
44. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000;288:669-672.